WS #10985
Bloomberg reports Zymeworks near $929M deal for Theravance at $17/share, a significant biotech M&A signal.
M&A Activity: Zymeworks-Theravance
Bloomberg reports Zymeworks near $929M deal for Theravance at $17/share, a significant biotech M&A signal.